You are here

  • Home
  • Archive
  • Volume 11, Issue Suppl 1
  • 601 Identification of non-squamous NSCLC molecular subtypes and association with outcomes in the phase 3 IMpower150 study of 1L atezolizumab ± bevacizumab + carboplatin-paclitaxel in metastatic NSCLC

Article metrics

Article menu

Download PDFPDF

Regular and Young Investigator Award Abstracts
Clinical Trial Completed
601 Identification of non-squamous NSCLC molecular subtypes and association with outcomes in the phase 3 IMpower150 study of 1L atezolizumab ± bevacizumab + carboplatin-paclitaxel in metastatic NSCLC

 

Online download statistics by month:

Online download statistics by month: November 2023 to June 2025

AbstractFullPdf
Nov 2023232015
Dec 20237307
Jan 20242202
Feb 20244603
Mar 20244601
Apr 20247603
May 20242800
Jun 20246601
Jul 20244605
Aug 20243202
Sep 20244401
Oct 20244204
Nov 20244403
Dec 20243006
Jan 20253904
Feb 20251605
Mar 2025001
Apr 2025006
May 2025003
Jun 20251010
Total883082